Tackling the EGFR in pathological tissue remodelling

Chan, Hsiu-Wen, Smith, Nicola J., Hannan, Ross D. and Thomas, Walter G. (2006) Tackling the EGFR in pathological tissue remodelling. Pulmonary Pharmacology and Therapeutics, 19 1: 74-78. doi:10.1016/j.pupt.2005.04.005


Author Chan, Hsiu-Wen
Smith, Nicola J.
Hannan, Ross D.
Thomas, Walter G.
Title Tackling the EGFR in pathological tissue remodelling
Journal name Pulmonary Pharmacology and Therapeutics   Check publisher's open access policy
ISSN 1094-5539
1522-9629
Publication date 2006-02-01
Year available 2005
Sub-type Article (original research)
DOI 10.1016/j.pupt.2005.04.005
Volume 19
Issue 1
Start page 74
End page 78
Total pages 5
Editor Clive Page
Place of publication London, U.K
Publisher Academic Press
Language eng
Subject 060108 Protein Trafficking
060110 Receptors and Membrane Biology
060111 Signal Transduction
060199 Biochemistry and Cell Biology not elsewhere classified
060602 Animal Physiology - Cell
110201 Cardiology (incl. Cardiovascular Diseases)
110903 Central Nervous System
Formatted abstract
Tissue remodelling is an adaptive physiological event initiated by physical and/or hormonal stimuli and characterised by extracellular matrix modifications, inflammation, cellular hypertrophy, proliferation and/or apoptosis. Although its initial effects may be beneficial for the maintenance of organ function, it is evident that sustained remodelling processes can lead to pathological outcomes, such as fibrosis in asthma, and cardiac hypertrophy in heart failure. Our research is focussed upon cardiac hypertrophy and the significant contribution of the molecular pathway, termed ‘the triple membrane-passing signalling’ paradigm (TMPS), to this phenomenon. Cardiac hypertrophy describes the enlargement, but not proliferation, of cardiomyocytes in response to mechanical or hormonal factors to normalise cardiac output and accompanies other features of cardiac remodelling. As a major independent risk factor for heart failure, it is imperative that the molecular mechanisms that govern this phenotype are determined to identify possible therapeutic targets. This review will focus on the importance of matrix metalloproteases and epidermal growth factor receptors in the TMPS pathway and their potential as pharmacological targets for heart failure therapy. The evidence provided may have implications for pathological tissue remodelling in other organs.
© 2005 Elsevier Ltd. All rights reserved.
Keyword Tissue remodelling
EGFR
Metalloprotease
Cardiac hypertrophy
Transactivation
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown
Additional Notes Available online 24 June 2005.

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Biomedical Sciences Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 20 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 23 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 15 Jan 2009, 19:17:39 EST by Ms Julie Anne Hansen on behalf of School of Biomedical Sciences